Ribociclib and letrozole - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Ribociclib and letrozole

Brand Name:

Kisqali Femara Co-pack

Strength:

200 mg/ 2.5 mg

HCPCS:

NA

SEER*Rx Category:

Chemotherapy

Hormonal Therapy

Major Drug Class:

Cyclin dependent kinase inhibitor/ aromatase inhibitor

Minor Drug Class:

CDK 4/6

Oral (Y/N):

Yes

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use